RIMA — A new concept in the treatment of depression with moclobemide

@article{Amrein1993RIMAA,
  title={RIMA — A new concept in the treatment of depression with moclobemide},
  author={R. Amrein and W. D. Hetzel and Max Stabl and W. Schmid-burgk},
  journal={International Clinical Psychopharmacology},
  year={1993},
  volume={7},
  pages={123–132}
}
Moclobemide, a specific reversible inhibitor of monoamine oxidase that shows a preference for the A isoenzyme, has been developed as a new antidepressive agent. Unlike earlier generation monoamine oxidase inhibitors, moclobemide is devoid of any clinically significant tyramine interaction, thus making dietary restrictions during therapy unnecessary. In comparative trials, moclobemide has been found to be superior to placebo and similar to imipramine, clomipramine, and amitriptyline in clinical… Expand
A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
TLDR
No difference in antidepressive efficacy between the two drugs, but imipramine had more anticholinergic side-effects and neither drug had significant effects on pulse rate, blood pressure, weight changes or blood chemistry. Expand
A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders
SummaryMoclobemide, a novel benzamide, is a reversible inhibitor of monoamine oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders.Expand
Clinical pharmacology of MAO inhibitors: safety and future.
TLDR
It seems obvious that a greater understanding of the pharmacodynamics and pharmacokinetics of MAOIs could result in improved treatment of the patients in the future, and selective MAO-B inhibitors and RIMAs hold promise as safer alternatives to classicalMAOIs. Expand
A review of the reversible MAO‐A inhibitor moclobemide in geriatric patients
TLDR
A comparison of the relevant literature shows that moclobemide has advantages over other, classic, antidepressants because of better tolerability, fewer side effects and interactions, shorter latency of effect, and lower toxicity. Expand
Efficacy, safety, and indications for tricyclic and newer antidepressants
TLDR
The SSRIs have demonstrated efficacy equivalent to TCAs, but possess more favorable side effect profiles and are safer in overdose than the classical tricyclic antidepressants and monoamine oxidase inhibitors, and to inform clinical decision-making. Expand
Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders
TLDR
Large placebo‐controlled studies have shown the activity of moclobemide in the depression that accompanies dementia (such as senile dementia of Alzheimer type) and suggested that, in this patient population, cognitive ability improved in parallel. Expand
Moclobemide in continuation treatment of major depressive episodes: an open follow-up study over six months.
TLDR
Moclobemide as continuation treatment of patients with major depressive episodes and comorbid anxiety was efficacious over a 6-month period, and there was some additional antidepressant effect after 6 weeks of acute treatment. Expand
Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
TLDR
The potentiation of tyramine-evoked mydriasis by moclobemide is likely to reflect the inhibition of MAO-A activity in the iris, consistent with the activity of this enzyme in sympathetic nerve terminals. Expand
Double‐blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression
TLDR
The differences between the two drugs were non‐significant for all types of side‐effect, with the exception of dry mouth and tachycardia, which were significantly more frequent with moclobemide. Expand
A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R)
TLDR
This was a prospective, double-blind, randomized, multicenter trial comparing moclobemide once daily (OD) with three times daily (TDS) dosing and efficacies were found not to differ significantly. Expand
...
1
2
3
...